Sabbatini 2013.

Methods	Randomised placebo‐controlled trial
Participants	888 ovarian cancer patients in complete clinical remission after primary therapy
Interventions	Subcutaneous monoclonal antibody (abagovomab ‐ CA‐125)
Outcomes	Survival (recurrence‐free survival, overall survival) Immune responses: humoral (Ab3, HAMA), cellular (to be reported in separate paper) Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Centralised randomisation
Allocation concealment (selection bias)	Low risk	Centralised randomisation
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Blinding of participants and key study personnel ensured; unlikely that the blinding could have been broken
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding of outcome assessment ensured; unlikely that the blinding could have been broken
Incomplete outcome data (attrition bias) All outcomes	Low risk	Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Other bias	Low risk	No other forms of bias detected